Molecular Weight(MW): 379.48
AZD1208 is a potent, and orally available Pim kinase inhibitor with IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively. Phase 1.
Cited by 17 Publications
6 Customer Reviews
Loss of proliferation in ATL-derived cell lines by the Pim-kinase inhibitor AZD1208 (D). Cell counts were repeated at least twice. Results represent the percentage of cells alive after 5 days of Pim inhibitor treatment, compared with 5 days treated with DMSO. For AZD1208, cells were treated with 0, 5, or 10 μM AZD1208. Normal PBMCs (n = 2) were used as a control. Western blots indicate loss of Pim1 targets, p-4EBP1 (Thr37/46), p-p70S6K (Thr389), and loss of pBad (Ser20) (negligible for Smi-4a) after 24 hours with 0, 5, or 10 μM AZD1208; or DMSO control.
Blood, 2016, 127(20):2439-50.. AZD1208 purchased from Selleck.
(D) IC50 values calculated from cell viability assays of indicated cell lines, with the top concentration for PIM447 and AZD1208 being 10 μM. Shown is the mean of four replicates ± SEM. (E) IC50 values calculated from cell viability assays of indicated cell lines, with the top concentration for AEB071 being 10 μM and 1 μM for Ibrutinib. Shown is the mean of four replicates ± SEM. (F) ABC DLBCL cell lines, grouped based on drug sensitivity, with known somatic mutations.
Oncotarget, 2016, 7(39):63362-63373. AZD1208 purchased from Selleck.
(D) HBL1 cells were plated in 0.9% MethoCult (1,000 cells/well) with vehicle, ibrutinib (100 or 1,000 nM), AZD-1208 (100 or 1,000 nM), or the combinations, and colony formation was scored after 7 days. Graphs represent quantifications of 3 wells, expressed as mean ± SD. (E) HBL1 tumor cells were implanted into CB17 SCID mice, and the indicated drugs were orally administered daily when the tumors reached 150 mm3. Tumors were measured twice a week. Significant tumor suppression was observed in the group treated with the ibrutinib/AZD-1208 combination compared with the vehicle-treated group (*P<0.01, repeated measures MANOVA-adjusted univariate F-test).
Am J Cancer Res, 2016, 6(11):2489-2501. AZD1208 purchased from Selleck.
Effect of the Pim1 inhibitor AZD1208 on the expression of NFIL3 (at 24 h) and viability of eosinophils (at 48 h) stimulated with IL-5 and Dex. A) AZD1208 at a concentration specific for inhibition of Pim1 activity (1ng/ml) blocked upregulation of NFIL3 by IL-5 and Dex/IL-5 (24 h) without a significant effect on Pim1 expression. B) Inhibition of Pim1 activity by AZD1208 blocked the anti-apoptotic effect of IL-5 and restored the proapoptotic effect of Dex on activated eosinophils, * p<0.05 vs. control cells. The error bars represent the standard deviation of 4 experiments from 3 independent donors.
Apoptosis, 2016, 21(4):421-31. AZD1208 purchased from Selleck.
Purity & Quality Control
Choose Selective Pim Inhibitors
|Description||AZD1208 is a potent, and orally available Pim kinase inhibitor with IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively. Phase 1.|
|Features||Orally bioavailable Pim kinase inhibitor that has been tested in Phase I clinical trials for treatment of advanced solid tumors and malignant lymphoma.|
AZD1208 is an orally available, potent and highly selective Pim inhibitor that effectively inhibits all three isoforms. AZD1208 inhibits the growth of several AML cell lines and sensitivity correlates with the level of Pim-1 expression, STAT5 activation and presence of protein tyrosine kinase mutation. AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells in culture. This is accompanied by a dose-dependent reduction in phosphorylation of BAD, 4EBP1 and p70S6K. In addition, AZD1208 leads to potent inhibition of colony growth of primary AML cells from bone marrow aspirates and downregulates phosphorylation of Pim targets. 
|In vivo||AZD1208 suppresses the growth of MOLM-16 and KG-1a xenograft tumors in vivo in a dose proportional manner. |
|In vitro||DMSO||75 mg/mL warmed (197.63 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
What is your recommended solvent of S7104 for mouse in vivo studies by oral administration?
1%CMC-Na is recommended and you will get a suspension. It is ok for oral administration.
I would like to ask which solvent I should use to dissolve AZD1208 for mouse study. Can AZD1208 be dissolved in 5% dextrose?
AZ1208 can be dissolved in 5% dextrose at 10 mg/ml as a suspension. If 5% Tween 80 added, the suspension will be more homogeneously.